A New Approach to Posterior Tibial Tendon Degeneration
Posterior tibial tendon dysfunction (PTTD) is resistant to standard conservative care and frequently leads to surgery. This observational cohort study, conducted in collaboration with University Foot & Ankle Institute and Regenative Labs, examined the safety and outcomes of Wharton’s Jelly (WJ) connective tissue allografts as a minimally invasive option for patients with PTTD.
Study Overview
- Design: Retrospective, multi-site observational cohort approved by the Institute of Regenerative and Cellular Medicine (IRCM)
- Participants: 26 patients with moderate-to-severe PTTD (Stages II–IV) who had failed ≥3 months of conservative care
- Intervention: 1 or 2 ultrasound-guided percutaneous applications of a 150 mg Wharton’s Jelly tissue allograft
- Follow-up: 30, 90, and 120 days post-procedure
“This study provides preliminary evidence that Wharton’s Jelly tissue allografts may be a safe and effective minimally invasive application for degeneration of the posterior tibial tendon.” — Biomedicines, 2025
Clinical Significance
The findings suggest that WJ tissue allografts may offer an early, regenerative-first intervention before surgical reconstruction becomes necessary. By supplementing damaged tendon tissue with a collagen-rich, biologically familiar matrix, this approach supports structure and function without altering the natural anatomy.
A Step Toward Evidence-Based Care
This publication adds to a growing body of Regenative Labs research demonstrating the homologous, connective-tissue-specific applications of Wharton’s Jelly in musculoskeletal care.